Filing Details

Accession Number:
0000899243-19-003683
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-02-14 18:01:24
Reporting Period:
2019-02-12
Accepted Time:
2019-02-14 18:01:24
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1708493 Harpoon Therapeutics Inc. HARP () X0
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1700449 Plc Bioscience Arix 20 Berkeley Square
Mayfair, London X0 W1J 6EQ
No No Yes No
1756884 Ltd Holdings Bioscience Arix 20 Berkeley Square
Mayfair, London X0 W1J 6EQ
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-02-12 2,463,548 $0.00 2,463,548 No 4 C Indirect See Footnote
Common Stock Acquisiton 2019-02-12 428,571 $14.00 2,892,119 No 4 P Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect See Footnote
No 4 P Indirect See Footnote
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series B Convertible Preferred Stock Disposition 2019-02-12 1,720,698 $0.00 1,720,698 $0.00
Common Stock Series C Convertible Preferred Stock Disposition 2019-02-12 742,850 $0.00 742,850 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Harpoon Therapeutics, Inc. (the "Issuer") common stock, on a one-for-one basis, effective upon closing of the Issuer's initial public offering.
  2. These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.